Integral Diagnostics is Australia’s fourth-largest diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
2008
2.0K+
LTM Revenue $374M
LTM EBITDA $71.4M
$834M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Integral Diagnostics has a last 12-month revenue of $374M and a last 12-month EBITDA of $71.4M.
In the most recent fiscal year, Integral Diagnostics achieved revenue of $297M and an EBITDA of $4.3M.
Integral Diagnostics expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Integral Diagnostics valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $278M | $297M | XXX | XXX | XXX |
Gross Profit | $215M | $265M | XXX | XXX | XXX |
Gross Margin | 77% | 89% | XXX | XXX | XXX |
EBITDA | $58.5M | $4.3M | XXX | XXX | XXX |
EBITDA Margin | 21% | 1% | XXX | XXX | XXX |
Net Profit | $9.2M | $15.8M | XXX | XXX | XXX |
Net Margin | 3% | 5% | XXX | XXX | XXX |
Net Debt | $63.2M | $120M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 14, 2025, Integral Diagnostics's stock price is AUD 2 (or $1).
Integral Diagnostics has current market cap of AUD 818M (or $517M), and EV of AUD 1.3B (or $834M).
See Integral Diagnostics trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$834M | $517M | XXX | XXX | XXX | XXX | $0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 14, 2025, Integral Diagnostics has market cap of $517M and EV of $834M.
Integral Diagnostics's trades at 2.2x LTM EV/Revenue multiple, and 11.7x LTM EBITDA.
Analysts estimate Integral Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Integral Diagnostics and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $834M | XXX | XXX | XXX |
EV/Revenue | 2.4x | XXX | XXX | XXX |
EV/EBITDA | 20.5x | XXX | XXX | XXX |
P/E | -51.7x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | 41.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpIntegral Diagnostics's NTM/LTM revenue growth is 28%
Integral Diagnostics's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Integral Diagnostics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Integral Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Integral Diagnostics and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 7% | XXX | XXX | XXX | XXX |
EBITDA Margin | 12% | XXX | XXX | XXX | XXX |
EBITDA Growth | -93% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | 40% | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 65% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
Opex to Revenue | 86% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
Compass Pathways | XXX | XXX | XXX | XXX | XXX | XXX |
Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Integral Diagnostics acquired XXX companies to date.
Last acquisition by Integral Diagnostics was XXXXXXXX, XXXXX XXXXX XXXXXX . Integral Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Integral Diagnostics founded? | Integral Diagnostics was founded in 2008. |
Where is Integral Diagnostics headquartered? | Integral Diagnostics is headquartered in Australia. |
How many employees does Integral Diagnostics have? | As of today, Integral Diagnostics has 2.0K+ employees. |
Who is the CEO of Integral Diagnostics? | Integral Diagnostics's CEO is Dr. Ian Kadish. |
Is Integral Diagnostics publicy listed? | Yes, Integral Diagnostics is a public company listed on ASX. |
What is the stock symbol of Integral Diagnostics? | Integral Diagnostics trades under IDX ticker. |
When did Integral Diagnostics go public? | Integral Diagnostics went public in 2015. |
Who are competitors of Integral Diagnostics? | Similar companies to Integral Diagnostics include e.g. Burjeel Holdings, PureHealth, Ramsay Health, Compass Pathways. |
What is the current market cap of Integral Diagnostics? | Integral Diagnostics's current market cap is $517M |
What is the current revenue of Integral Diagnostics? | Integral Diagnostics's last 12-month revenue is $374M. |
What is the current EBITDA of Integral Diagnostics? | Integral Diagnostics's last 12-month EBITDA is $71.4M. |
What is the current EV/Revenue multiple of Integral Diagnostics? | Current revenue multiple of Integral Diagnostics is 2.2x. |
What is the current EV/EBITDA multiple of Integral Diagnostics? | Current EBITDA multiple of Integral Diagnostics is 11.7x. |
What is the current revenue growth of Integral Diagnostics? | Integral Diagnostics revenue growth between 2023 and 2024 was 7%. |
Is Integral Diagnostics profitable? | Yes, Integral Diagnostics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.